Compare AFYA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | TRVI |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2019 | 2019 |
| Metric | AFYA | TRVI |
|---|---|---|
| Price | $14.05 | $14.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $17.00 | ★ $21.55 |
| AVG Volume (30 Days) | 66.0K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.43 | N/A |
| Revenue Next Year | $7.15 | N/A |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.00 | $5.38 |
| 52 Week High | $19.76 | $16.12 |
| Indicator | AFYA | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 58.93 |
| Support Level | $13.06 | $10.07 |
| Resistance Level | $15.50 | $16.12 |
| Average True Range (ATR) | 0.55 | 0.79 |
| MACD | -0.10 | -0.09 |
| Stochastic Oscillator | 7.36 | 56.64 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.